Cognate BioServices, now part of Charles River, is a leading brand in the field of cell and gene therapy development, testing, and manufacturing. With this acquisition, Charles River has become a premier scientific partner for clients, offering an integrated solution from basic research to CGMP production. Alongside Cognate BioServices, Charles River has partnered with other industry leaders in this space, including Cobra Biologics and Vigene Biosciences, to provide customers with a comprehensive and trusted approach to cell and gene products.

They offer a range of services, including cell sourcing, safety assessment, laboratory sciences, and biologics testing solutions. Additionally, their expertise extends to various therapeutic areas, such as COVID-19, cardiovascular disease, immunology, and oncology. With Cognate BioServices as part of Charles River, clients can benefit from their industry-leading cell therapy CDMO services, including viral vector and plasmid DNA solutions.

Stay connected with Cognate BioServices and receive the latest news and insights in the field of cell and gene therapy